Influvac, a trivalent inactivated subunit influenza vaccine

Bibliography

• Center for Disease Control and Prevention. Prevention and control of influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2010;59(RR 8):1-62
   PubMedGoogle Scholar
• Izurieta HS, Thompson WW, Kramarz P, Influenza and the rates of hospitalization for respiratory disease among infants and young children. N Engl J Med 2000;342:232-9
   PubMed Web of Science ®Google Scholar
• Influenza (seasonal) World Health Organization. Fact sheet No 211. Geneva, Switzerland: WHO, 2009. Available from: www.who.int/mediacentre/factsheets/fs211/en/index.html [Last accessed 20 November 2010]
   Google Scholar
• Neuzil KM, Mellen BG, Wright PF, The effect of influenza on hospitalizations, outpatient visit, and courses of antibiotics in children. N Engl J Med 2000;342:225-31
   PubMed Web of Science ®Google Scholar
• Molinari NA, Ortega-Sanchez IR, Messonnier ML, The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 2007;25:5086-96
   PubMed Web of Science ®Google Scholar
• World Health Organization. Influenza vaccines. Wkly Epidemiol Rec 2000;75:281-8
   Google Scholar
• Smith DJ, Lapedes AS, de Jong JC, Mapping the antigenic and genetic evolution of influenza virus. Science 2004;305:371-6
   PubMed Web of Science ®Google Scholar
• Jain S, Kamimoto L, Bramley AM, Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med 2009;361:1935-44
   PubMed Web of Science ®Google Scholar
• Miller E, Hoschler K, Hardelid P, Incidence of 2009 pandemic influenza A H1N1 in England: a cross-sectional serological study. Lancet 2010;375:1100-8
   PubMed Web of Science ®Google Scholar
• Nichel KM, Margolis KL, Wuorenma J, The efficacy and cost-effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 1994;331:778-84
   PubMed Web of Science ®Google Scholar
• Maciosek MW, Solberg LI, Coffield AB, Influenza vaccination health impact and cost effectiveness among adults aged 50 to 64 and 65 and older. Am J Perv Med 2006;31:72-9
   PubMed Web of Science ®Google Scholar
• Muennig PA, Khan K. Cost-effectiveness of vaccination versus treatment of influenza in healthy adolescents and adults. Clin Infect Dis 2001;33:1879-85
   PubMed Web of Science ®Google Scholar
• Newall AT, Schuffham PA, Kelly H, The cost-effectiveness of universal influenza vaccination program for adults aged 50-64 years in Australia. Vaccine 2008;26:2142-53
   PubMed Web of Science ®Google Scholar
• Colombo GL, Ferro A, Vinci M, Cost-benefit analysis of influenza vaccination in a public healthcare unit. Ther Clin Risk Manag 2006;2:219-26
   PubMedGoogle Scholar
• Salo H, Kilpi T, Sintonen H, Cost-effectiveness of influenza vaccination of healthy children. Vaccine 2006;24:4934-41
   PubMed Web of Science ®Google Scholar
• Esposito S, Marchisio P, Bosis S, Clinical and economic impact of influenza vaccination on healthy children aged 2-5 years. Vaccine 2006;24:629-35
   PubMed Web of Science ®Google Scholar
• Navas E, Salleras L, Dominguez A, Cost-effectiveness analysis of inactivated virosomal subunit influenza vaccination in children aged 3-14 years from the provider and societal perspectives. Vaccine 2007;25:3233-9
   PubMed Web of Science ®Google Scholar
• Fleming DM, Elliot AJ. Health benefits, risks, and cost-effectiveness of influenza vaccination in children. Pediatr Infect Dis J 2008;27:S154-8
   PubMedGoogle Scholar
• Jefferson T, Smith S, Demicheli V, Assessment of the efficacy and effectiveness of influenza vaccines in healthy children: systematic review. Lancet 2005;365:773-80
   PubMed Web of Science ®Google Scholar
• Fiore AE, Bridges CB, Cox NJ. Seasonal influenza vaccines. Curr Top Microbiol Immun 2009;333:43-82
   PubMedGoogle Scholar
• IFPMA IVS International Task Force. Influenza vaccine distribution in 141 countries, 2004–2007. Third European Influenza Conference, Vilamoura, Portugal, September 14 – 17, 2008 Available from: http://www.ifpma.org/influenza/content/pdfs/Publications/2008_09_Influenza_Vaccine_distribution_in_141_countries.pdf [Last accessed 20 Novmber 2010]
   Google Scholar
• Provinciali M, Di Stefano G, Muzzioli M, Impaired antibody response to influenza vaccine in institutionalized elderly. Ann NY Acad sci 1994;717:307-14
   PubMed Web of Science ®Google Scholar
• Nichol KL, Wuorenma J, von Sternberg T. Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens. Arch Intern Med 1998;158:1769-76
   PubMed Web of Science ®Google Scholar
• Beyer WEP, Palache AM, Osterhaus ADME. Comparison of serology and reactogenicity between influenza subunit vaccines and whole virus or split vaccines. Clin Drug Invest 1998;15:1-12
   PubMed Web of Science ®Google Scholar
• Beran J, Vesikari T, Wertzova V, Efficacy of inactivated split-virus influenza vaccine against culture-confirmed influenza in healthy adults: a prospective, randomized, placebo-controlled trial. J Infect Dis 2009;200:1861-9
   PubMed Web of Science ®Google Scholar
• Jackson LA, Gagliani MJ, Keyserling HL, Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in healthy adults: a randomized, placebo-controlled trial over two influenza seasons. BMC Infect Dis 2010;10:71
   PubMed Web of Science ®Google Scholar
• Nichol KL. The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines. Vaccine 2003;21:1769-75
   PubMed Web of Science ®Google Scholar
• De Diego C, Vila-Corcoles A, Ochoa O, Effects of annual influenza vaccination on winter mortality in elderly people with chronic heart disease. Eur Heart J 2009;30:209-16
   PubMed Web of Science ®Google Scholar
• Poole PJ, Chacko E, Wood-Baker RW, Influenza vaccines for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006;1:CD002733
   PubMed Web of Science ®Google Scholar
• Atashili J, Kalilani L, Adimora AA. Efficacy and clinical effectiveness of influenza vaccines in HIV-infected individuals: a meta-analysis. BMC Infect Dis 2006;6:138
   PubMed Web of Science ®Google Scholar
• Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 2006;24:1159-69
   PubMed Web of Science ®Google Scholar
• O'Hagan DT. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. Expert Rev Vaccines 2007;6:669-710
   Google Scholar
• Ott G, Barchfeld GL, Van Nest G. Enhancement of humoral response against human influenza vaccines with simple submicron oil/water emulsion adjuvant MF59. Vaccine 1995;13:1557-62
   PubMed Web of Science ®Google Scholar
• Banzhoff A, Nacci P, Podda A. A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis. Gerontolgy 2003;49:177-84
   PubMed Web of Science ®Google Scholar
• Baldo V, Baldovin T, Floreani A, MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18-60 years of age) with chronic diseases who at risk of post-influenza complications. Vaccine 2007;25:3955-61
   PubMed Web of Science ®Google Scholar
• Vesikari T, Pellegrini M, Karvonen A, Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr Infect Dis J 2009;28:563-71
   PubMed Web of Science ®Google Scholar
• Vesikari T, Groth N, Karvonen A, MF59-adjuvanted influenza vaccine (FLUAD) in children: safety ad immunogenicity following a second year seasonal vaccination. Vaccine 2009;27:6291-5
   PubMed Web of Science ®Google Scholar
• Baldo V, Baldovin T, Pellegrini M, Immunogenicity of three different influenza vaccines against homologous and heterologous strains in nursing home elderly residents. Clin Dev Immunol 2010;2010:517198
   PubMedGoogle Scholar
• Ansaldi F, Canepa P, Parodi V, Adjuvanted seasonal influenza vaccines and perpetual viral metamorphosis: the importance of cross-protection. Vaccine 2009;27:3877-82
   Web of Science ®Google Scholar
• Pellegrini M, Nicholay U, Lindert K, MF59-adjuvanted versus non-adjuvanted influenza vaccines: interated analysis from a large safety database. Vaccine 2009;27:6959-65
   PubMed Web of Science ®Google Scholar
• Zurbriggen R. Immunostimolating reconstituted influenza virosomes. Vaccine 2003;21:921-4
   PubMed Web of Science ®Google Scholar
• Bungener L, Serre K, Bijl L, Virosome-mediated delivery of protein antigens to dendritic cells. Vaccine 2002;20:2287-95
   PubMed Web of Science ®Google Scholar
• de Bruijn IA, Nauta J, Cramer WC, Clinical experience with inactivated, virosomal influenza vaccine. Vaccine 2005;23:S39-49
   PubMed Web of Science ®Google Scholar
• Herzog C, Hartmann K, Kunzi V, Eleven years of Inflexal V-a virosomal adjuvanted influenza vaccine. Vaccine 2009;27:4381-7
   PubMed Web of Science ®Google Scholar
• Gluck R, Mischler R, Finkel B, Immunogenicity of new virosome influenza vaccine in elderly people. Lancet 1994;344:160-3
   PubMed Web of Science ®Google Scholar
• Zuccotti GV, Amendola A, Vigano A, Long-term immunogenicity of a virosomal subunit inactivated influenza vaccine in children with asthma. Vaccine 2007;25:6692-8
   PubMed Web of Science ®Google Scholar
• Zuccotti GV, Scaramuzza A, Riboni S, Long-lasting immunogenicity of a virosomal vaccine in older children and young adults with type I diabetes mellitus. Vaccine 2009;27:5357-62
   PubMed Web of Science ®Google Scholar
• Vigano A, Zuccotti GV, Pacei M, Humoral and cellular response to influenza vaccine in HIV-infected children with full immunovirologic response to antiretroviral therapy. J Acquir Immune Defic Syndr 2008;48:289-96
   PubMed Web of Science ®Google Scholar
• Amendola A, Pariani E, Vigano A, Influenza surveillance in a cohort of HIV-infected children and adolescents immunized against seasonal influenza. Vaccine 2010;28:2700-4
   Google Scholar
• First nasal Mist Flu Vaccine Approved. 2003, June 17 [cited 2008 August 20]. Available from: http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm123753.htm
   Google Scholar
• Belshe RB, Gruber WC, Mendelman PM, Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr 2000;136:168-75
   PubMed Web of Science ®Google Scholar
• Treanor JJ, Kotloff K, Betts RR, Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (N1H1), A (H3N2), and B viruses. Vaccine 1999;18:899-906
   PubMed Web of Science ®Google Scholar
• Cox NJ, Bridges CB. Inactivated and live attenuated influenza vaccines in young children-how do they compare? N Engl J Med 2007;356:729-31
   PubMed Web of Science ®Google Scholar
• Belshe RB, Ambrose CS, Tingting YI. Safety and efficacy of live attenuated influenza vaccine in children 2-7 years of age. Vaccine 2008;26S:D10-16
   Web of Science ®Google Scholar
• Allan RS, Waithman J, Bedoui S, Migratory dendritic cells transfer antigen to a lymph node-resident dendritic cell population for efficient CTL priming. Immunity 2006;25:153-62
   PubMed Web of Science ®Google Scholar
• Reddy ST, van d V, Siconi E, Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat Biotechnol 2007;25:1159-64
   PubMed Web of Science ®Google Scholar
• Kenney RT, Frech SA, Muenz LR, Dose sparing with intradermal injection of influenza vaccine. N Engl J Med 2004;351:2295-301
   PubMed Web of Science ®Google Scholar
• Belghe RB, Newman FK, Cannon J, Serum antibody responses after intradermal vaccination against influenza. N Engl J Med 2004;351:2286-94
   PubMed Web of Science ®Google Scholar
• Belshe RB, Newman FK, Wilkins K, Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults. Vaccine 2007;25:6755-63
   PubMed Web of Science ®Google Scholar
• Chiu SS, Peiris JS, Chan KH, Immunogenicity and safety of intradermal influenza immunization at a reduced dose in healthy children. Pediatrics 2007;19:1076-82
   Web of Science ®Google Scholar
• Sugimura T, Ito Y, Tananari Y, Improved antibody responses in infants less than 1 year old using intradermal influenza vaccination. Vaccine 2008;26:2700-5
   PubMed Web of Science ®Google Scholar
• Audsley MJ, Tannock GA. Cell-based influenza vaccines. Drugs 2008;68:1483-91
   PubMed Web of Science ®Google Scholar
• Hoelscher M, Gangappa S, Zhong W, Vaccines against epidemic and pandemic influenza. Expert Opin Drug Deliv 2008;5:1139-57
   PubMed Web of Science ®Google Scholar
• Ulmer JB, Donnelly JJ, Parker SE, Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993;259:1745-9
   PubMed Web of Science ®Google Scholar
• Donnelly JJ, Friedman A, Martinez D, Preclinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift in influenza virus. Nat Med 1995;1:583-7
   PubMed Web of Science ®Google Scholar
• Donnelly JJ, Friedman A, Ulmer Jb, Further protection against antigenic drift of influenza virus in a ferret model by DNA vaccination. Vaccine 1997;15:865-8
   PubMed Web of Science ®Google Scholar
• Drape RJ, Macklin MD, Barr LJ, Epidermal DNA vaccine for influenza is immunogenic in humans. Vaccine 2006;24:4475-81
   PubMed Web of Science ®Google Scholar
• Epstein SL, Kong WP, Misplon JA, Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine 2005;23:5404-10
   PubMed Web of Science ®Google Scholar
• Zhao G, Lin Y, Guan J, An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses. Virol J 2010;18:9
   Web of Science ®Google Scholar
• Oxford JS, Schild GC, Potter CW, The specificity of the anti-haemagglutinin antibody response induced in man by inactivated influenza vaccines and by natural infection. J Hyg 1979;82:51-61
   PubMedGoogle Scholar
• Cox RJ, Brokstad KA, Zuckerman MA, An early humoral immune response in peripheral blood following parenteral inactivated influenza vaccination. Vaccine 1994;12:993-9
   PubMed Web of Science ®Google Scholar
• Zuckerman MA, Cox R, Taylor J, Rapid immune response to influenza vaccination. Lancet 1993;342:1113
   PubMed Web of Science ®Google Scholar
• Nichol KL. Efficacy/clinical effectiveness of inactivated influenza vaccines in adults. In: Nicholson KG, Webster RG, Hay AJ, editors. Textbook of influenza. Blackwell Science, Oxford, UK; 1998a. p. 358-72
   Google Scholar
• Neuzil KM, Dupont WD, Wright PF, Efficacy of inactivated and cold-adapted vaccines against influenza A infection 1985 to 1990: the pediatric experience. Pediatr Infect Dis J 2001;20:733-40
   PubMed Web of Science ®Google Scholar
• La Montagne JR, Noble GR, Quinnan GV, Summary of clinical trials of inactivated influenza vaccine, 1978. Rev Infect Dis 1983;5:723-36
   PubMedGoogle Scholar
• Brokstad KA, Cox RJ, Major D, Cross-reaction but no avidity change of the serum antibody response after influenza vaccination. Vaccine 1995;13:1522-8
   PubMed Web of Science ®Google Scholar
• El-Madhun AS, Cox RJ, Haaheim LR. The effect of age and natural priming on the IgG and IgA subclass response after parenteral influenza vaccination. J Infect Dis 1999;180:1356-60
   PubMed Web of Science ®Google Scholar
• Foy HM, Cooney MK, McMahan R. A Hong Kong influenza immunity three years after immunization. JAMA 1973;226:758-61
   PubMed Web of Science ®Google Scholar
• Couch RB, Keitel WA, Cate TR. Prevention of influenza virus infection by current inactivated influenza vaccines. In: Brown LE, Hampson AW, Webster RG, editors. Options for the control of influenza III. Elsevier, Amsterdam, Netherlands; 1996. p. 97-106
   Google Scholar
• Committee for Proprietary Medicinal Products. Note for Guidance on Harmonization of Requirements for Influenza Vaccines. CPMP/BWP/214/96, European Medicines Agency, London, UK; 1997. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003945.pdf [Last accessed 20 November 2010]
   Google Scholar
• Giezeman KM, Nauta J, de Bruijn IA, Trivalent inactivated subunit influenza vaccine Influvac®: 25-Year experience of safety and immunogenicity. Vaccine 2009;27:2414-17
   PubMed Web of Science ®Google Scholar
• Palache AM, Nauta J, de Regt V, Twenty years' experience with safety and immunogenicity of an inactivated subunit influenza vaccine. J Drug Assess 2005;8:1-15
   Google Scholar
• De Bruijn I, Meyer I, Gerez L, Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly. Vaccine 2007;26:119-27
   PubMed Web of Science ®Google Scholar
• Zhu FC, Zhou W, Pan H, Safety and immunogenicity of two subunit influenza vaccines in healthy children, adults and the elderly: a randomized controlled trial in China. Vaccine 2008;26:4579-85
   PubMed Web of Science ®Google Scholar
• Burtseva E, Slepushkin AN, Vlasova LN, Comparative evaluation of the reactogenicity and immunogenicity of inactivated influenza vaccines in the elderly. Zh Mikrobiol Epidemiol Immunobiol 2000;5:40-5
   PubMedGoogle Scholar
• Ghendon YZ, Kaira AN, Elshina GA. The effect of mass immunization in children on the morbidity of the unvaccinated elderly. Epidemiol Infect 2006;134:71-8
   PubMed Web of Science ®Google Scholar
• Daubeney P, Taylor CJ, McGraw J, Immunogenicity and tolerability of a trivalent influenza subunit vaccine (Influvac®) in high-risk children aged 6 months to 4 years. Br J Clin Pract 1997;51:87-90
   PubMedGoogle Scholar
• Kramarz P, DeStefano F, Gargiullo PM, Influenza vaccination in children with asthma in health maintenance organizations: Vaccine Safety Datalink Team. Vaccine 2000;18:2288-94
   PubMed Web of Science ®Google Scholar
• Bueving HJ, van der Wouden JC, Raat H, Influenza vaccination in asthmatic children: effects on quality of life and symptoms. Eur Resp J 2004;24:925-31
   PubMed Web of Science ®Google Scholar
• Bueving HJ, Bernsen RMD, da Jongste JC, Influenza vaccination in children with asthma. Randomized double-blind placebo-controlled trial. Am J Respir Crit Care Med 2004;169:486-93
   Web of Science ®Google Scholar
• Bueving HJ, Bernsen RMD, da Jongste JC, Does influenza vaccination exacerbate asthma in children? Vaccine 2004;23:91-6
   PubMed Web of Science ®Google Scholar
• Schaad UB, Buhlmann U, Burger R, Comparison of immunogenicity and safety of a virosome influenza vaccine with those of a subunit influenza vaccine in pediatric patients with Cystic fibrosis. Antimicrob Agents Chemother 2000;44:1163-7
   PubMed Web of Science ®Google Scholar
• Brydak LB, Rokicka-Milewska R, Machala M, Immunogenicity of subunit trivalent influenza vaccine in children with acute lymphoblastic leukaemia. Pediatr Infect Dis J 1998;17:125-9
   PubMed Web of Science ®Google Scholar
• Palache AM. Influenza sub-unit vaccine-ten years' experience. Eu J Clin Res 1992;3:117-38
   Google Scholar
• Palache AM, de Bruijn IA, Nauta J. Influenza immunisation. I: Influenza vaccination policies and new vaccine developments. II: Fifteen years' experience with a subunit influenza vaccine. J Clin Res 1990;2:111-39
   Google Scholar
• Walter EB, Rajagopal S, Zhu Y, Trivalent inactivated influenza vaccine (TIV) immunogenicity in children 6 through 23 months of age: do children of all ages respond equally? Vaccine 2010;28:4376-83
   Google Scholar
• Hambridge SJ, Glanz JM, France EK, Safety of trivalent inactivated influenza vaccine in children 6 to 23 months old. JAMA 2006;296:1190-7
   Google Scholar
• Reuben FL. Inactivated influenza vaccines in children. Clin Infect Dis 2004;38:678-88
   PubMed Web of Science ®Google Scholar
• Beran J, Vesikari T, Wertzova V, Efficacy of inactivated split-virus influenza vaccine against culture-confirmed influenza in healthy adults: a prospective, randomized, placebo-controlled trial. J Infect Dis 2009;200:1861-9
   PubMed Web of Science ®Google Scholar
• Corsetti E, Arniani S, Bordoni F, Effectiveness of influenza vaccination in the elderly in a community in Italy. Eur J Epidemiol 2001;17:163-8
   PubMed Web of Science ®Google Scholar
• Vu T, Farish S, Jenkins M, A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community. Vaccine 2002;20:1831-6
   PubMed Web of Science ®Google Scholar
• CDC. Surveillance for influenza-United States, 1997-98, 1998-99, and 1999-2000 seasons. Morbidity and Mortality Weekly Report 2002;51:1-10
   Google Scholar
• de Jong JC, Palanche AM, Beyer WE, Haemoagglutination-inhibiting antibody to influenza virus. Develop Biol 2003;115:63-73
   Google Scholar
• Beyer WEP, Palanche AM, Osterhaus ADME, Comparison of serology and reactogenicity between influenza subunit vaccines and whole virus or split vaccines. Clin Drug Invest 1998;15:1-12
   PubMed Web of Science ®Google Scholar
• Cox RJ, Brokstad KA, Ograt P. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand J Immunol 2004;59:1-15
   PubMed Web of Science ®Google Scholar
• Ruf BR, Colberg K, Frick M, Open, randomized study to compare the immunogenicity and reactogenicity of an influenza split vaccine with an MF59-adjuvanted subunit vaccine and a virosome-based subunit vaccine in elderly. Infection 2004;32:191-8
   PubMed Web of Science ®Google Scholar
• Kanra G, Marchisio P, Feiterna-Sperling C, Comparison of immunogenicity and tolerability of a virosome adjuvanted and a split influenza vaccine in children. Pediatr Infect Dis J 2004;23:300-6
   PubMed Web of Science ®Google Scholar
• Emmanuel BW, Englund JA, Blatter M, Trivalent inactivated influenza virus vaccine given to two-months-old children. Pediatr Infect Dis J 2009;28:1099-104
   PubMed Web of Science ®Google Scholar
• Halasa NB, Gerber MA, Chen Q, Safety and immunogenicity of trivalent inactivated influenza vaccine in infants. J Infect Dis 2008;197:1448-54
   PubMed Web of Science ®Google Scholar